To boldly lead

Arthritis in space and time--to boldly go!

Despite the profound impact of biologics on the treatment of rheumatoid arthritis (RA), long lasting disease remission remains elusive. We propose that this is a consequence of failing to target the right molecular pathway in the most relevant patient group at the appropriate time and place in disease progression. A limitation to testing this approach is the availability of disease models repre...

Boldly Targeting Kinases without mutations.

and those arising in the context of viral infections remains to be elucidated. These entities share with MBL the indolent course and the low propensity to progress to overt malignancy. Among the patients followed for 5 years, only 17% of them progressed to clinically overt, splenic B-cell lymphoma of MZ origin, and only 3 needed treatment over the follow-up time. It is likely that CBL-MZ repres...

Personality Science: Exploring Boldly, Integrating Creatively

that members of one guild will not be on speaking terms with those of another. But the integrative aspirations of personality science will require theories that explicitly seek to bridge the isolated islands of research and this will require an ecumenical attitude toward colleagues of diverse faiths. We now have several metatheoreti-cal frameworks for personality science that will remain an imp...

To Boldly Go: Bayesian Exploration for Mobile Robots

To BOLDly go where positron emission tomography has been before.

Atherosclerotic disease remains concealed for many years and becomes clinically overt only when the growth of atherosclerotic plaques and the adverse remodeling of the arterial wall reach a critical stage that results in impairment of blood flow, ischemia, and angina. Large epicardial arteries have a diameter ranging from a few millimeters to 500 m and are visible at coronary angiography. Prear...